Evoke Pharma Cmn (EVOK) 1.92 $EVOK 3 Healthcare Stocks

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Evoke Pharma Cmn (EVOK) 1.92 $EVOK

3 Healthcare Stocks Poised to Beat Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 10:26AM CDT
in the second quarter, results have managed to outpace expectations so far.
EVOK: 1.92 (-0.05), AST: 2.79 (+0.05), ORPN: 1.62 (-0.06)

Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter 2016 on Monday, August 15, 2016, after the close of the market.
EVOK: 1.92 (-0.05)

Evoke Pharma Completes Credit Facility Repayment
GlobeNewswire - Mon Aug 08, 7:30AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company" , a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced it has paid all of the outstanding amounts of indebtedness under its loan and security agreement (the "Credit Facility" with Square 1 Bank, a division of Pacific Western Bank. With the repayment of this $4.5 million of debt, Evoke will eliminate interest expenses from the facility of approximately $250,000 a year.
EVOK: 1.92 (-0.05)

Evoke Pharma Announces $10 Million Registered Direct Offering Priced At-The-Market
GlobeNewswire - Fri Jul 29, 2:15PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK) ("Evoke Pharma" or "the Company" , today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $10 million in a registered direct offering priced at the market price. The closing of the offering is expected to take place on or about August 3, 2016, subject to the satisfaction of customary closing conditions.
EVOK: 1.92 (-0.05)

4 Companies Demonstrate High Volume & Volatility Today Friday 7/29/2016
PR Newswire - Fri Jul 29, 10:30AM CDT
TechStockInsider.com Briefing: The small & mid-cap markets are experiencing high volume and volatility today Friday 7/29/16. Below we discuss 4 companies that demonstrate above average volume and volatility.
EVOK: 1.92 (-0.05), CLD: 4.13 (+0.04), TSRI: 6.54 (+0.26)

Four Companies To Consider for Your Portfolio in August 2016
PR Newswire - Thu Jul 28, 11:45AM CDT
TechStockInsider.com Briefing: The Fed held its two-day meeting this week and after much deliberation, the decision has been made to leave rates where they are for right now. The guidance came after identifying that the current economic state is still relatively unstable while the outlook for the global economic unrest mainly rippling from Brexit have still some uncertainty. Despite this outlook on the economy, the decision actually has spurred interest in many stocks this morning with many "bottomed out" equities seeing price reversals including:
EVOK: 1.92 (-0.05), EBIO: 4.88 (+0.15), SPU: 12.60 (+4.28)

Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that the last subject completed treatment in its pivotal Phase 3 study for EVK-001, the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The primary endpoint in the four-week, U.S. multicenter, randomized, double-blind, placebo-controlled clinical trial is the change in gastroparesis symptoms at week 4 utilizing a proprietary Patient Report Outcome (PRO) symptom assessment instrument. The Company expects to report top-line Phase 3 study results early in the third quarter of 2016.
EVOK: 1.92 (-0.05)

Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
GlobeNewswire - Tue May 24, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from its successful thorough electrocardiogram (ECG) study of EVK-001, its patented nasal delivery formulation of metoclopramide for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis in women, were presented at Digestive Disease Week (DDW) 2016.
EVOK: 1.92 (-0.05)

Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
GlobeNewswire - Thu May 19, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001. EVK-001 is the Company's novel nasal spray for delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women.
EVOK: 1.92 (-0.05)

Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:00AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter 2016 on Wednesday, May 11, 2016, after the close of the market.
EVOK: 1.92 (-0.05)

Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
GlobeNewswire - Tue May 03, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of 2016. The study was designed to enroll approximately 200 subjects and the Company has confirmed that 205 subjects have now been randomized in the trial. EVK-001 is the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 1.92 (-0.05)

Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Mon Apr 25, 7:01AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 1.92 (-0.05)

What's Next for KaloBios as Shkreli Faces Fraud Charges?
Arpita Dutt - Zacks Investment Research - Fri Dec 18, 1:55PM CST
KaloBios' (KBIO) shares slumped more than 50% in pre-market trading following the arrest of CEO Martin Shkreli.
EVOK: 1.92 (-0.05), MYL: 42.36 (-0.39), AMPH: 19.00 (-0.45)

Did the Wu-Tang Clan Rat Out Martin Shkreli to SEC?
David Bartosiak - Zacks Investment Research - Thu Dec 17, 3:47PM CST
Notorious Biopharma CEO Martin Shkreli finds out the hard way that the SEC ain’t nothing to mess with.
EVOK: 1.92 (-0.05), RTRX: 16.02 (-0.15), MYL: 42.36 (-0.39), AMPH: 19.00 (-0.45)

Evoke Pharma Reports Third Quarter 2015 Results
GlobeNewswire - Thu Nov 12, 3:10PM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2015.
EVOK: 1.92 (-0.05)

Evoke to Participate in the Brean Capital 2015 Life Sciences Summit
GlobeNewswire - Tue Nov 10, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be participating in the Brean Capital 2015 Life Sciences Summit on Monday, November 16, 2015 at the Millennium Broadway Hotel in New York City.
EVOK: 1.92 (-0.05)

Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 05, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of the market.
EVOK: 1.92 (-0.05)

Diabetic Gastroparesis - Pipeline Review, H2 2015
M2 - Fri Oct 23, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7t58rx/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline Plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc For more information visit http://www.researchandmarkets.com/research/7t58rx/diabetic
EVOK: 1.92 (-0.05), IRWD: 13.34 (-0.08), SHPG: 187.18 (-3.04), GSK: 43.46 (+0.10), CEMP: 21.94 (+0.50)

Evoke Pharma Strengthens Financial Position
GlobeNewswire - Wed Oct 07, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the amendment of its loan and security agreement with Square 1 Bank (the "credit facility" to extend the interest-only payment term for an additional 12 months. Furthermore, through cash management and At-The-Market equity placements under its agreement with MLV & Co. LLC, Evoke had an estimated $10.7 million in cash as of September 30, 2015, an increase of $0.8 million from June 30, 2015. The Company now projects that its current cash resources should be sufficient to fund operations through October 2016.
EVOK: 1.92 (-0.05)

Evoke fulfils 75% patient enrollment in Phase 3 clinical trial under credit agreemnt
M2 - Tue Sep 29, 6:02AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) said on Monday that it has reached a key milestone under its USD4.5m loan, security and credit agreement with Square 1 Bank.
EVOK: 1.92 (-0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 129

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 146

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 139

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 66

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Raises Price Target for Blackstone Amid Encouraging Outlook

Updated Category News Views 131

Citi's Updated Outlook on Blackstone Recently, Citi revisited its financial forecast for The Blackstone Group (NYSE: BX), adjusting the price target upward from $157.00 to $170.00 while maintaining a Neutral stance on the stock. This update follows the company's impressive third-quarter performance, which saw Blackstone's stock rise by 6.3% post-earnings announcement....

Continue Reading
JAB's Strategic Acquisition of Mondelez Shares in JDE Peet's

Updated Category News Views 92

JAB's Significant Move in the Coffee Industry In a strategic and noteworthy development, JAB has made headlines by agreeing to acquire a substantial share package from Mondelez, focusing on Dutch coffee giant JDE Peet's. This major transaction amounts to approximately €2.2 billion, or about $2.4 billion. JAB intends to purchase 86 million shares at a price of €25.10...

Continue Reading
Urgent Update for DXC Technology Company Investors

Updated Category News Views 272

DXC Technology Company (NYSE: DXC) found itself in hot water back in 2024 when shareholders raised hell over alleged falsehoods that inflated stock prices. The Rosen Law Firm rolled out a class action lawsuit aimed at those who bought shares during what they dubbed the Class Period—a time rife with questionable operational claims from DXC's brass. Allegations Surface:...

Continue Reading
Investigation Launched: National Grid Faces Legal Scrutiny

Updated Category News Views 283

Bragar Eagel & Squire, P.C. Initiates Investigation Bragar Eagel & Squire, P.C., a well-regarded law firm known for advocating for investors, has begun an investigation surrounding concerns related to National Grid plc (NYSE: NGG). This inquiry primarily aims to assist stockholders who may have experienced losses while owning shares of National Grid. The firm invites...

Continue Reading
Oil & Gas Sector Trends: Path to 8.79 Trillion Growth

Updated Category News Views 223

Oil & Gas Market Growth and Projections The global oil and gas market has positioned itself for remarkable expansion. With estimates currently valuing the market at approximately USD 6.10 trillion, projections suggest it could soar to around USD 8.79 trillion by 2034. This growth translates to a compound annual growth rate (CAGR) of 3.72% between 2025 and 2034. Notably,...

Continue Reading